⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12860960 | 1.00 | — | — | |
| SCHEMBL14290005 | 1.00 | — | — | |
| SCHEMBL8255222 | 1.00 | — | — | |
| SCHEMBL5872389 | 1.00 | — | — | |
| SCHEMBL16921041 | 1.00 | — | — | |
| SCHEMBL8248640 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL23004591 | 0.98 | CTSC (0.35) | — | |
| Hydrochloric Acid SCHEMBL29013660 | 0.98 | CTSC (0.35) | — | |
| Hydrochloric Acid SCHEMBL29013662 | 0.98 | CTSC (0.35) | — | |
| SCHEMBL16399741 | 0.80 | GLI1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025124698-A1 | ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-19 | — | — | WO | disclosed |
| WO-2023227698-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| EP-4125914-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11564908-B2 | Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder | GLYCOLYSIS BIOMED CO., LTD. (TW) | 2023-01-31 | — | — | US | disclosed |
| CN-114591212-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2020151671-A1 | BETA-LACTAM COMPOUNDS OR SALTS THEREOF FOR USE IN LONG-ACTING PREVENTION OR TREATMENT OF A GLUCOSE METABOLISM DISORDER | GLYCOLYSIS BIOMED CO., LTD (CN) | 2020-07-30 | — | — | WO | disclosed |
| US-20200230149-A1 | BETA-LACTAM COMPOUNDS OR SALTS THEREOF FOR USE IN LONG-ACTING PREVENTION OR TREATMENT OF A GLUCOSE METABOLISM DISORDER | GLYCOLYSIS BIOMED CO., LTD. (TW) | 2020-07-23 | — | — | US | disclosed |
| CN-105612153-B | Substituted heterocyclic sulfonamide compound as TRPA1 conditioning agents | 豪夫迈·罗氏有限公司 | 2018-09-14 | — | — | CN | disclosed |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2018-07-24 | — | — | US | disclosed |
| US-9498540-B2 | Cell proliferation inhibitors and conjugates thereof | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| US-9393239-B2 | Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2016-07-19 | — | — | US | disclosed |
| US-20140221341-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETALACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| EP-1658066-B9 | ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1658066-B1 | ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2009-09-30 | — | — | EP | disclosed |